Physician profile
Ralph Denatale
NPI 1497790026
$1,275.72
in general payments reported to CMS, 2019-2025
11 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2021: $42.32 · 2022: $202 · 2023: $108 · 2024: $475 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $579.31 | 2019-2025 | Ranger, Opticross 35, General - Vascular Intervention |
| Alphatec Spine, INC | $172.04 | 2024 | Identiti |
| Silk Road Medical, INC. | $164.58 | 2019 | |
| Endologix LLC | $114.40 | 2023-2024 | Afx2 Bifurcated Endograft System |
| Smith+Nephew, INC. | $81.96 | 2022-2025 | Renasys Touch, Grafix Pl |
| Lemaitre Vascular, INC. | $46.38 | 2019-2025 | Xenosure Biologic Patch |
| Cordis US Corp. | $33.05 | 2023-2025 | Mynx Control Venous, Zephyr |
| Reprise Biomedical, INC. | $27.46 | 2023 | Miro3d |
| Janssen Pharmaceuticals, INC | $23.92 | 2021 | |
| Convatec INC. | $18.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Denatale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.